

IDENTIFICATION OF PHARMACOLOGICAL CHAPERONES FOR THE CELLULAR PRION PROTEIN BY DYNAMIC MASS REDISTRIBUTION (DMR) SCREENING

Iglesias A², Elezgarai SR^{3,8}, Barreca ML⁵, Moreno J⁶, García-Martínez S⁶, Castilla J^{6,7}, Loza M², Biasini E^{4,8}, Domínguez E², Requena JR¹

¹CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, Spain; ²BioFarma Group, CIMUS Biomedical Research Institute, University of Santiago de Compostela, Spain; ³Department of Molecular Biochemistry and Pharmacology and ⁴Department of Neuroscience, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; ⁵Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, Perugia, Italy; ⁶CIC bioGUNE, Parque tecnológico de Bizkaia, Derio 48160, Bizkaia, Spain; ⁷IKERBASQUE, Basque Foundation for Science, Bilbao 48011, Bizkaia, Spain; ⁸Dulbecco Telethon Institute, Centre for Integrative Biology (CIBIO), University of Trento, Trento, Italy.

INTRODUCTION

Genetic prion diseases are fatal dominantly inherited neurodegenerative disorders linked to mutations in the *PRNP* gene encoding the prion protein (PrP) that cause protein misfolding in the brain and led to devastating neurologic defects and dead. Although a number of molecules have been tested in humans no pharmacological treatment with efficacy to prevent neurological symptoms or prolong survival time exists. D178N mutation is causal¹ and triggers the conversion of the cellular prion protein (PrP^C) into an aggregated form (PrP^{Sc}) that self-propagates in the brain by imposing its abnormal conformation^{2,3}. This concept provides a rationale for tackling aggregation by stabilizing the PrP^C monomeric protein precursors by increasing the Gibbs free energy barrier (ΔG) required for the initial misfolding events. This goal could potentially be achieved with ligands of PrP^C that act as pharmacological chaperones stabilizing PrP^C protein (Fig. 1). An european consortium of prion biology and drug discovery experts was established to identify novel small molecules targeting prion disease.




Fig.1. Scheme of the funnel-shaped free-energy surface that proteins explore as they move towards the native state by forming intramolecular contacts³. The free-energy landscape results in the accumulation of kinetically trapped conformations that need to traverse free-energy barriers and these steps may be accelerated by chaperones. When several molecules fold simultaneously in the same compartment, the free-energy surface of folding may overlap with that of intermolecular aggregation, resulting in the formation of amorphous aggregates, toxic oligomers or ordered amyloid fibrils.

OBJECTIVE

To develop a novel screening method based on Dynamic Mass Redistribution (DMR), a label-free, fully automated biophysical technique, capable of detecting small molecule-prion protein interactions.

MATERIAL AND METHODS

Recombinant Human PrP23-230 (recHuPrP23-230) was expressed in *E. coli*. Inclusion bodies were solubilized in 2M guanidine-containing buffer and the protein attached to an NTA affinity column. The protein, which has intrinsic affinity for metals, and attaches to the column through its histidine-containing octarepeat sequence, was allowed to fold while attached by gradual elimination of the guanidine. Folded recHuPrP23-230 was then eluted by application of 500 mM imidazole, and dialyzed against 50 mM sodium acetate, pH 5. Protein concentration was determined from its A_{280} and proper folding assessed by CD spectroscopy. DMR assay starts with the activation of LFB 384-well microplates (PerkinElmer 6057468) with 15 μ l activation buffer (400 mM EDC + 100 mM Sulfo-NHS) and incubation for 30 min at R.T. Immobilization of HuPrP^C protein (20 μ g/ml for first screening and 15 μ g/ml for the second screening) is done in 10 mM Sodium acetate buffer pH 6 and incubating overnight at 4°C. The compounds were screened at 10 μ M and incubated for 30 min. Light refraction signal of tested compounds was measured in PerkinElmer EnSpire® Multimode Plate Reader for 48 min (1 read /2 min). Signals obtained at 24 min were used as final readouts. We developed two screening campaigns, one for Prestwick® chemical library and other a virtual selection of potentially (small molecules crossing the blood-brain barrier from a total of 60.000 compounds present in USEF. Active compounds (average + 3 SD for first screening and average + 2 SD for second screening) (Fig 2 and Fig 4, respectively) were selected for cherry picking and triaged by Protein Misfolding Cyclic Amplification (PMCA) assay⁴ (Fig 3 and Fig 5). PMCA is a technique that mimics prion replication *in vitro* with similar efficiency to the *in vivo* process. It is based on cycles of sonication/incubations. After each cycle, the number of prions are amplified in an exponential fashion. The rationale to use this technique to evaluate anti-prion compounds is based on the high impact that any kind of inhibition of the *in vitro* prion replication process will have in the amplification of the final amount of prions.

RESULTS




Fig.2. Label-free signals from High Throughput Screening (HTS) campaign of Prestwick® chemical library (1280 compounds) at 10 μ M in human PrP^C. The hit Threshold was fixed at average + 3SD and 13 hits were identified. Black circles represents the tested compounds, blue square represents negative control (Buffer) and red square represents positive control Tetrapyrrole (TMPyP-Fe(III)). At the top right of the figure shows the metric parameters and dose-response curve for positive control Tetrapyrrole.




Fig.4. Label-free signals from HTS campaign of selected compounds from USEF (3888 compounds) at 10 μ M in human PrP^C. The hit Threshold was fixed at average + 2SD and 11 hits were identified. Black circles represents the tested compounds, blue square represents negative control (Buffer) and red square represents positive control Tetrapyrrole. At the top right of the figure shows the metric parameters and dose-response curve for positive control Tetrapyrrole.




Fig.3. Active compounds which stabilize the conformation of human PrP^C identified on first DMR-based HTS campaign were identified. A) HTS hits tested at 10 μ M. B) Dose-response curve of CBG030937 indicating a micromolar activity in DMR assay. C) *In vitro* PrP^{res} amplification by rec-PMCA with or without CBG030937 50 μ l of human rec-PrP complemented with chicken brain homogenate, seeded with different dilutions of human recombinant prion (1:10³ – 1:10¹¹) were mixed with 0.5 μ l of DMSO, TMPyP-Fe(III) (used as positive control) or CBG030937 diluted in DMSO (at final concentration of 250 μ M) and subjected to a unique 48 h round of rec-PMCA. Amplified samples were digested with 50 μ g/ml of proteinase K (PK) and analyzed by western blot using monoclonal antibody 3F4 (1:10,000). Fe(III)-TMPyP and CBG030937 exhibited a potent inhibitory activity toward the amplification of human recombinant prion of at least 10⁶ fold. NBH: Normal brain homogenate. MW: Molecular marker.




Fig.5. Active compounds which stabilize the conformation of human PrP^C identified on second DMR-based HTS campaign were later confirmed by cherry picking assays at 10 μ M.

CONCLUSIONS

- Our results demonstrated that DMR is a reliable platform for the identification of novel pharmacological chaperones targeting the cellular prion protein.
- We have identified molecules that might interact with prion protein. One of them is an existing drug used in neurological disorders and antiproliferative activity that stands out from others for its high affinity. Moreover, it inhibits in a dose-dependent manner the conversion of PrP^C into PrP^{Sc}, the key molecular event of prion disease. A range of assays (e.g., biochemical, biophysical, cell-based), along with computational chemistry approaches are being performed to validate the hits.

REFERENCES

1. Minikel, E. V. *et al. Sci. Transl. Med.* 8, 322ra9 (2016)
2. Vázquez-Fernández, E. *et al. Plos Pathog.* 12, (2016)
3. Hartl, F.U. *et al. Nature.* 475, 324-332 (2011)
4. Saborio, G. P. *et al. Nature.* 411, 810-813 (2001)

FUNDING

- Project CHAPRION. Pharmacological chaperones for genetic prion diseases. Call E-RARE. HORIZON 2020. Instituto Carlos III Ref: AC14/00018
- INNOPHARMA. Plataforma de farmacogenómica aplicada a la validación de dianas y descubrimiento de fármacos candidatos a fases preclínicas. Technology Funds. Ministry of Economy and Competitiveness and European Regional Development Fund (ERDF).

